S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
LON:RLM

Realm Therapeutics (RLM) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
11.50
11.50
52-Week Range
N/A
Volume
169,853 shs
Average Volume
800,861 shs
Market Capitalization
£13.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Realm Therapeutics

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

RLM Stock News Headlines

Defence of the Realm Act (DORA)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Realm Therapeutics PLC ADR (RLM_old)
See More Headlines
Receive RLM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Realm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£501,919.00
Book Value
GBX 20.80 per share

Miscellaneous

Free Float
N/A
Market Cap
£13.41 million
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. John Alexander Martin (Age 51)
    CEO & Exec. Director
  • Ms. Marella Thorell (Age 52)
    CFO, COO, Company Sec. & Exec. Director
  • Dr. Christian Peters (Age 57)
    Chief Medical Officer

RLM Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Realm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Realm Therapeutics investors own include Allena Pharmaceuticals (ALNA), AcelRx Pharmaceuticals (ACRX), Ampliphi Biosciences (APHB), Viking Therapeutics (VKTX), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS).

How do I buy shares of Realm Therapeutics?

Shares of RLM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:RLM) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners